Investigating multi-modal therapy with radiotherapy, vascular-targeted photodynamic therapy and immunotherapy in pre-clinical models of prostate cancer by Philippou, Y

Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study by Philippou, Y, Protheroe, AS, Bryant, RJ

Harnessing the potential of multimodal radiotherapy in prostate cancer by Philippou, Y, Sjoberg, H, Lamb, AD, Camilleri, P, Bryant, RJ

Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis by Philippou, Y, Harriss, E, Davies, L, Jubber, I, Leslie, T, Bell, R, Bryant, R, Hamdy, F, Verrill, C, Lamb, A

Progress in clinical research in surgery and IDEAL by McCulloch, P, Feinberg, J, Philippou, Y, Kolias, A, Kehoe, S, Lancaster, G, Donovan, J, Petrinic, T, Agha, R, Pennell, C

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic di... by Charlton, PV, O'Reilly, D, Philippou, Y, Rao, SR, Lamb, ADG, Mills, IG, Higgins, GS, Hamdy, FC, Verrill, C, Buffa, FM, Bryant, RJ

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic di... by Charlton, P, O’Reilly, D, Philippou, Y, Rao, SR, Lamb, AD, Mills, IG, Higgins, G, Hamdy, FC, Verrill, C, Buffa, FM, Bryant, RJ

Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification? by Bryant, R, Yang, B, Philippou, Y, Lam, K, Obiakor, M, Ayers, J, Chiocchia, V, Gleeson, F, MacPherson, R, Verrill, C, Sooriakumaran, P, Hamdy, F, Brewster, S

No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations by Hirst, A, Philippou, Y, Blazeby, J, Campbell, B, Campbell, M, Feinberg, J, Rovers, M, Blencowe, N, Pennel, C, Quinn, T, Rogers, W, Cook, J, Kolias, A, Agha, R, Dahm, P, Sedrakyan, A, McCulloch, P

Ductal adenocarcinoma of the prostate: A systematic review and meta‐analysis of incidence, presentation, prognosis, and management by Ranasinha, N, Omer, A, Philippou, Y, Harriss, E, Davies, L, Chow, K, Chetta, PM, Erickson, A, Rajakumar, T, Mills, IG, Bryant, RJ, Hamdy, FC, Murphy, DG, Loda, M, Hovens, CM, Corcoran, NM, Verrill, C, Lamb, AD

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model by Philippou, Y, Sjoberg, HT, Murphy, E, Alyacoubi, S, Jones, KI, Gordon-Weeks, AN, Phyu, S, Parkes, EE, McKenna, WG, Lamb, AD, Gileadi, U, Cerundolo, V, Scheiblin, DA, Lockett, SL, Wink, DA, Mills, IG, Hamdy, FC, Muschel, RJ, Bryant, RJ

Tumour irradiation combined with vascular-targeted photodynamic therapy enhances anti-tumour effects in preclinical prostate cancer by Sjoberg, H, Philippou, Y, Magnussen, A, Tullis, I, Bridges, E, Chatrian, A, Lefebvre, J, Tam, KH, Murphy, E, Rittscher, J, Preise, D, Agemy, L, Yechezkel, T, Smart, S, Kinchesh, P, Gilchrist, S, Allen, D, Scheiblin, D, Lockett, S, Wink, D, Lamb, A, Mills, I, Harris, A, Muschel, R, Vojnovic, B, Scherz, A, Hamdy, F, Bryant, R

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer by Fletcher, CE, Deng, L, Orafidiya, F, Yuan, W, Lorentzen, MPGS, Cyran, OW, Varela-Carver, A, Constantin, TA, Leach, DA, Dobbs, FM, Figueiredo, I, Gurel, B, Parkes, E, Bogdan, D, Pereira, RR, Zhao, SG, Neeb, A, Issa, F, Hester, J, Kudo, H, Liu, Y, Philippou, Y, Bristow, R, Knudsen, K, Bryant, RJ, Feng, FY, Reed, SH, Mills, IG, de Bono, J, Bevan, CL